Sanofi
Pasteur MSD has appointed David Khougazian as its new president, a role he will
take up on September 1, when he will succeed Dr Jean-Paul Kress at the
Sanofi Pasteur - Merck & Co venture.
Kress, who has led the company since July 2011, will then leave Sanofi Pasteur MSD to join the Sanofi group - which recently announced a major restructuring of its business.
Khougazian moves to the vaccines-focused firm from a position as Sanofi CEO chief of staff, which he held since 2011.
Prior to this he had a number of business operations positions in sales and marketing and as general manager, having joined Rhône-Poulenc (now part of Sanofi) in 1997.
Olivier Charmeil, president and CEO of Sanofi Pasteur, said: “Sanofi Pasteur MSD is a major player in the European vaccines market. David's appointment marks a new phase in our development in Western Europe; a challenging and strategic region for our vaccines activity.
“His knowledge of European markets and external stakeholders will be a strong asset to grow Sanofi Pasteur MSD's position in Europe.”
No results were found
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...